Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06942182 | Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures | PHASE2 | NOT YET_RECRUITING | 60 | — | — | May 1, 2025 | Mar 1, 2026 | Apr 24, 2025 | - | — |
| Arm | Type | Description |
|---|---|---|
| Study Drug: 1000 mg Isomyosamine | EXPERIMENTAL | Subjects randomly assigned to receive 1000 mg Isomyosamine daily via four 250 mg capsules |
| Placebo 1000 mg | PLACEBO_COMPARATOR | Subjects randomly assigned to receive 1000 mg placebo daily via four 250 mg capsules |
| Name | Type | Description |
|---|---|---|
| Isomyosamine 250mg | DRUG | Isomyosamine 250 mg capsules dosed 4 times daily |
| Placebo 250 mg | DRUG | Placebo 250 mg capsule 4 times daily |
Inclusion Criteria: 1. Age 60 to 85 years of age 2. Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall 3. Concomitant medication limited to treatment for chronic conditions 4. The ability to give informe...